| Nov 14 |
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)
|
| Nov 8 |
Knight Therapeutics (TSE:GUD) investors are sitting on a loss of 33% if they invested five years ago
|
| Nov 8 |
Knight Therapeutics Inc (KHTRF) Q3 2024 Earnings Call Highlights: Revenue Growth Amidst Margin ...
|
| Nov 7 |
Knight Therapeutics Reports Third Quarter 2024
|
| Oct 31 |
Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call
|
| Oct 15 |
Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico
|
| Oct 9 |
Knight Therapeutics Inc (KHTRF) Q2 2024 Earnings Call Highlights: Record Revenues and Strategic ...
|
| Sep 27 |
Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies
|
| Sep 10 |
Top TSX Growth Companies With High Insider Ownership In September 2024
|
| Sep 9 |
3 High Insider Owned TSX Growth Companies With Earnings Up To 66%
|
